Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies

被引：0
|
作者：
Le, X. [1 ]
Prelaj, A. [2 ]
Baik, C. [3 ]
Tchekmedyian, N. [4 ]
Leu, S. [5 ]
Bhat, G. [5 ]
Heymach, J. V. [1 ]
Cornelissen, R. [6 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Ist Nazl Tumori Milano Fdn IRCCS, Milan, Italy
[3] Seattle Canc Ctr Alliance, Seattle, WA USA
[4] City Hope Natl Med Ctr, Irvine, CA USA
[5] Spectrum Pharmaceut, Irvine, CA USA
[6] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
HER2; exon20; poziotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.09
引用
收藏
页码：S147 / S148
页数：2
相关论文
共 50 条
  • [1] Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies
    Prelaj, A.
    Le, X.
    Proto, C.
    Baik, C. S.
    Tchekmedyian, N.
    Heymach, J.
    Bhat, G.
    Cornelissen, R.
    ANNALS OF ONCOLOGY, 2023, 34
  • [2] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [3] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
    Cornelissen, R.
    Garassino, M. C.
    Le, X.
    Clarke, J.
    Tchekmedyian, N.
    Goldman, J.
    Lebel, F.
    Bhat, G.
    Socinski, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S174
  • [5] Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
    Prelaj, Arsela
    Bottiglieri, Achille
    Proto, Claudia
    Lo Russo, Giuseppe
    Signorelli, Diego
    Ferrara, Roberto
    Galli, Giulia
    De Toma, Alessandro
    Viscardi, Giuseppe
    Brambilla, Marta
    Lobefaro, Riccardo
    Nichetti, Federico
    Manglaviti, Sara
    Occhipinti, Mario
    Labianca, Alice
    Ganzinelli, Monica
    Gallucci, Rosaria
    Zilembo, Nicoletta
    Greco, Gabriella Francesca
    Torri, Valter
    de Braud, Filippo
    Garassino, Marina C.
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 235 - 248
  • [6] Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
    Borm, Frank. J.
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 964 - 966
  • [7] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
    Socinski, M. A.
    Cornelissen, R.
    Garassino, M. C.
    Clarke, J.
    Tchekmedyian, N.
    Molina, J.
    Goldman, J. W.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
  • [8] Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5).
    Le, Xiuning
    Shum, Elaine
    Suga, Jennifer M.
    Brahmer, Julie R.
    Dooms, Christophe
    Mamdani, Hirva
    Nechushtan, Hovav
    Riess, Jonathan W.
    Spira, Alexander
    Barrett, John A.
    Dreiling, Lyndah K.
    Socinski, Mark
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
    Cornelissen, R.
    Sun, S.
    Wollner, M.
    Garassino, M. C. C.
    Prelaj, A.
    Haura, E. B.
    Piotrowska, Z.
    Goldman, J. W.
    Socinski, M.
    Dreling, L.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S1324 - S1324
  • [10] Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
    Prelaj, A.
    Bottiglieri, A.
    Proto, C.
    Lo Russo, G.
    Signorelli, D.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Viscardi, G.
    Brambilla, M.
    Lobefaro, R.
    Manglaviti, S.
    Occhipinti, M.
    Labianca, A.
    Gallucci, R.
    Molino, G.
    Zilembo, N.
    Greco, F. G.
    Torri, V.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S882 - S882
12345